Prestige BioPharma focuses on discovery and development of innovative new biologics as well as biosimilars.

PBP's first biosimilar HD201, Trastuzumab, successfully completed Phase I clinical trial in EU in 2014 and currently under Phase III development.

PBP thrives to become one of the top biopharmaceuticals specializing in discovery of new biologics and next series of biosimilars.

Our Pipeline

2 Science Park Drive #04-13/14
Ascent Tower B

Singapore Science Park

Singapore 118222

Prestige BioPharma

Phone: +65 6924 6535

Fax: +65 6924 2053


Prestige BioPharma Pte Ltd

Creating Differences & Value for Human Health

News & Resources

Discovery and Development of New Biologics and Biosimilars

PBP's R&D facilities located in the Biomedical Park of Singapore boast well-equipped multidisciplinary research infrastructure, supporting pharmaceutical R&D activities from discovery to nonclinical and clinical development.                             Read More


  • HD201, Trastuzumab 
  • HD204, Bevacizumab
  • PBP1502, Adalimumab
  • PBP1503, Biobetter, Bevacizumab
  • PBP1510, New antibody for pancreatic cancer treatment
  • PBP1505, Infliximab
  • PBP1506, Rituximab
  • PBP1507, Etanercept
  • PBP brochure including technical information on HD201 and HD204 is available upon request. Please email us at  to request a copy.
  • PBP will be participating at the upcoming BIO2016, June 6-9, 2016, Moscone Center, San Francisco, California, USA.